Edward You is a Supervisory Special Agent in the FBI’s Weapons of Mass Destruction Directorate, currently detailed as a Liaison Officer at the Department of Health and Human Services, Office of National Security. Mr. You is responsible for creating programs and activities to coordinate and improve FBI and interagency activities to identify, assess, and respond to biological threats or incidents. He supports FBI initiatives to build partnerships with the life sciences community, domestically and internationally, and leads efforts to identify and address potential security challenges in advanced biotechnology. His overall goal is to safeguard the scientific community, the life science research enterprise, and the U.S. bioeconomy. Before being promoted to the Weapons of Mass Destruction Directorate, Mr. You served as a member of the FBI Los Angeles Field Office Joint Terrorism Task Force and the FBI Hazardous Evidence Response Team.
Mr. You has also been directly involved in policy-making efforts with a focus on biosecurity. He served as an active Working Group member of the White House National Security Council Policy Coordinating Committee on Countering Biological Threats and represented the FBI as an Ex Officio member of the National Institutes of Health National Science Advisory Board for Biosecurity. He also served on two National Academies of Sciences, Engineering, and Medicine Committees, the Institute of Medicine’s Forum on Microbial Threats and the Committee on Science, Technology, and Law’s Forum on Synthetic Biology. He is currently a Senior Fellow for the Scowcroft Institute of International Affairs at the Bush School of Government and Public Service at Texas A&M University.
Prior to joining the FBI, Mr. You had extensive experience in academic research having worked for three years in autoimmune disease research at the Cedars-Sinai Medical Center and six years in human gene therapy and retrovirology at the University of Southern California, Keck School of Medicine. Just prior to joining the FBI, Mr. You worked for three years in the commercial biotechnology sector conducting cancer research and assay development at AMGEN, Inc.